Related Experiment Videos
Fluoxetine trial in suicidal depressed alcoholics
J R Cornelius1, I M Salloum, M D Cornelius
1Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburg Medical Center, PA 15213.
Psychopharmacology Bulletin
|January 1, 1993
Summary
Fluoxetine, a selective serotonin agonist, effectively treated depression and alcohol use in 12 patients with both conditions. The study found no increase in suicidal thoughts, suggesting fluoxetine
Area of Science:
- Psychiatry
- Clinical Pharmacology
Background:
- Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine are established treatments for major depressive disorder.
- SSRIs have shown potential in managing alcohol dependence, but data in comorbid depressed alcoholics is limited.
- Co-occurring depression and alcoholism present complex treatment challenges, including elevated suicide risk.
Purpose of the Study:
- To evaluate the efficacy and safety of fluoxetine in patients with comorbid major depressive disorder and alcohol dependence.
- To assess the impact of fluoxetine on depressive symptoms and alcohol consumption in this patient population.
Main Methods:
- An open-label study involving 12 inpatients diagnosed with major depressive disorder and alcohol dependence.
- Patients received fluoxetine (20-40 mg daily) for 8 weeks.
- Assessments included measures of depression, alcohol consumption, and suicidality.
Main Results:
- Statistically significant improvements were observed in depression scores.
- A significant reduction in post-discharge alcohol consumption was noted.
- No paradoxical increase in suicidal ideation or behavior was observed during treatment.
Conclusions:
- Fluoxetine demonstrates potential as a therapeutic agent for individuals suffering from both depression and alcoholism.
- The findings suggest fluoxetine can effectively manage depressive symptoms and reduce alcohol intake in this complex patient group.
- Further controlled trials are warranted to confirm these promising results.